Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high-grade serous ovarian cancer (HGSOC). We used targeted sequencing (TS) to analyze 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2023-09, Vol.29 (18), p.3706-3716
Hauptverfasser:	Lheureux, Stephanie, Prokopec, Stephenie D, Oldfield, Leslie E, Gonzalez-Ochoa, Eduardo, Bruce, Jeffrey P, Wong, Derek, Danesh, Arnavaz, Torti, Dax, Torchia, Jonathan, Fortuna, Alexander, Singh, Sharanjit, Irving, Matthew, Marsh, Kayla, Lam, Bernard, Speers, Vanessa, Yosifova, Aleksandra, Oaknin, Ana, Madariaga, Ainhoa, Dhani, Neesha C, Bowering, Valerie, Oza, Amit M, Pugh, Trevor J
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use BRCA1 Protein - genetics BRCA2 Protein - genetics Cell-Free Nucleic Acids - genetics Circulating Tumor DNA - genetics Female Humans Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Precision Medicine and Imaging
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!